Castle Biosciences, Inc. (CSTL) 2026 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good afternoon and welcome to the Castle Biosciences second quarter 2026 conference call as a reminder today's call is being recorded. We will begin today's call with opening remarks and introductions followed by a question-and-answer session. I would like to turn the call over to Camilla Zuckero Vice President Investor Relations and Corporate Affairs.

    下午好,歡迎參加 Castle Biosciences 2026 年第二季財報電話會議;提醒各位,今天的電話會議將被錄音。我們將以開場致詞與介紹開始,接著進行問答環節。現在我想把電話交給投資人關係與企業事務副總裁 Camilla Zuckero。

  • Camilla Zuckero - Investor Relations & Corporate Affairs

    Camilla Zuckero - Investor Relations & Corporate Affairs

  • Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences' second quarter 2026 results conference call. Joining me today are Castle's Founder, President, and Chief Executive Officer, Derek Maetzold; and Chief Financial Officer, Frank Stokes. Information recorded on this call speaks only as of today, July 30, 2026.

    謝謝,接線員。各位下午好。歡迎參加 Castle Biosciences 2026 年第二季業績電話會議。今天與我一同出席的有 Castle 創辦人、總裁兼執行長 Derek Maetzold,以及財務長 Frank Stokes。本通話中所提及之資訊僅截至今日(2026 年 7 月 30 日)為準。

  • Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the investor relations page of the company's website for approximately three weeks following the conclusion of the call.

    因此,若您收聽重播或閱讀本通話逐字稿,任何具時效性的資訊可能已不再準確。今日通話的錄音將於會議結束後約三週內,提供於公司網站的投資人關係頁面。

  • Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements. including statements about expected addressable markets, statements containing projections regarding future events or our future financial or operational results and performance, including our anticipated 2026 total revenue and the impact of our investments in growth initiatives, including our ability to achieve long-term growth and drive stockholder value.

    在開始之前,我想提醒各位,今天部分陳述將包含前瞻性聲明,包括關於預期可服務市場(addressable markets)的陳述、包含對未來事件或我們未來財務或營運結果與表現之預測的陳述,其中包括我們對 2026 年總營收的預期,以及我們在成長計畫上的投資影響,包括我們達成長期成長並提升股東價值的能力。

  • Forward-looking statements are based upon current expectations and involve inherent risks and uncertainties, and there can be no assurances that the results contemplated in these statements will be realized. A number of factors and risks could cause actual results to differ materially from those contained in these forward-looking statements. Please refer to the risk factors in our most recent SEC filings for more information. These forward-looking statements speak only as of today and we assume no obligation to update or revise these forward-looking statements as circumstances change.

    前瞻性聲明係基於目前的預期,並涉及固有風險與不確定性,且無法保證這些聲明所預期的結果一定能實現。多項因素與風險可能導致實際結果與這些前瞻性聲明所述內容出現重大差異。更多資訊請參閱我們最近向 SEC 提交文件中的風險因素。這些前瞻性聲明僅截至今日為準,且我們不承擔因情勢變化而更新或修訂任何前瞻性聲明之義務。

  • In addition, some of the information discussed today includes non-GAAP financial measures such as adjusted revenue, adjusted gross margin and adjusted EBITDA that have not been calculated in accordance with US GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today. Which has been posted on the investor relations page of the company's website.

    此外,今天討論的部分資訊包含非 GAAP 財務衡量指標,例如調整後營收、調整後毛利率與調整後 EBITDA,這些指標並非依照美國 GAAP 計算。這些非 GAAP 財務衡量指標與最直接可比的 GAAP 財務衡量指標之調節表,已列示於我們今日稍早發布之財報新聞稿末尾的表格中。該新聞稿已張貼於公司網站的投資人關係頁面。

  • I will now turn the call over to Derek.

    現在我把電話交給 Derek。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Thank you, Camilla, and good afternoon, everyone. What a great quarter. Our team across all areas at Castle did a phenomenal job in executing on our growth plans and pulling it through the business. Including revenue on the top line in evidence development and clinical research.

    謝謝你,Camilla,各位下午好。這是一個非常出色的季度。Castle 各部門團隊在執行我們的成長計畫並將成果落實到業務上,表現非常卓越。包括在營收端的表現,以及在證據開發與臨床研究方面的推進。

  • Thanks to the efforts by our team and the clinical value that our clinicians see in the actionability of our tests, we delivered revenue of $103.5 million, 20% growth compared to the second quarter of 2025. Furthermore, if we exclude DecisionDx-SCC and IDgenetix revenue for both 2026 and 2025, our revenue growth for the second quarter of 2026 was 40%. compared to the second quarter of 2025. Test report volume for our core revenue drivers grew 32% compared to the second quarter of 2025.

    在團隊努力以及臨床醫師看見我們檢測在可行動性(actionability)上的臨床價值之下,我們實現營收 1.035 億美元,較 2025 年第二季成長 20%。此外,若我們在 2026 與 2025 兩年度皆排除 DecisionDx-SCC 與 IDgenetix 的營收,則 2026 年第二季相較 2025 年第二季的營收成長為 40%。我們核心營收驅動產品的檢測報告量,較 2025 年第二季成長 32%。

  • Our strong second quarter results reflect the continued execution of our growth strategy, and we remain focused on investing thoughtfully in the future growth of Castle. We continue to invest in commercial resources to drive adoption of our tests, generate the clinical evidence needed to support reimbursement and expand adoption. Advanced pipeline opportunities across our dermatology and gastroenterology offerings, and add to laboratory capacity, technology, and personnel needs to support future growth. Supported by our robust balance sheet, we believe these investments position us to capitalize on the opportunities across our current portfolio and pipeline while maintaining a disciplined approach to capital allocation.

    我們第二季的強勁成果反映出成長策略持續落實執行;我們仍專注於以審慎方式投資 Castle 未來的成長。我們持續投資商業資源,以推動檢測採用、產生支持給付(reimbursement)所需的臨床證據,並擴大採用。同時推進皮膚科與腸胃科產品線的先進研發管線機會,並擴充實驗室產能、技術與人力需求,以支援未來成長。在強健資產負債表的支持下,我們相信這些投資能使我們在維持嚴謹資本配置紀律的同時,把握現有產品組合與研發管線的機會。

  • We believe we will continue this positive momentum in the second half of 2026. And our strong second quarter performance gives us the confidence to raise our 2026 total revenue guidance to $365 million to $375 million, compared to the previously provided guidance of $345 million to $355 million.

    我們相信在 2026 年下半年將延續這股正向動能。而第二季的強勁表現也讓我們有信心將 2026 年總營收指引上調至 3.65 億至 3.75 億美元,高於先前提供的 3.45 億至 3.55 億美元指引。

  • Now, I will walk you through the business highlights in the second quarter, and then Frank will provide additional financial highlights before we turn to your questions. Let's start with our four revenue drivers for 2026. DecisionDx melanoma and tissue ciphering. For DecisionDx melanoma, we delivered 10,280 test reports in the second quarter, representing 3% growth compared to the second quarter of 2025.

    接下來我將帶各位回顧第二季的業務重點,之後 Frank 會補充更多財務重點,然後我們再進入提問。先從我們 2026 年的四大營收驅動因素談起。DecisionDx melanoma 與 TissueCypher。就 DecisionDx melanoma 而言,我們在第二季交付 10,280 份檢測報告,較 2025 年第二季成長 3%。

  • We are on track to meet our expectations of mid to high single-digit volume growth for the full year 2026 over 2025. DecisionDx melanoma test volume also increased approximately 3% in the second quarter of 2026, compared with the first quarter of 2026, representing moderate sequential growth, though below the sequential increase we typically see based upon historical seasonality. We believe this moderate sequential growth was due in part to our commercial team adapting its customer engagement model to support three products within the same customer call. This is a deliberate investment in the growth of our business.

    我們正按計畫達成對 2026 全年相較 2025 年「中至高個位數」量能成長的預期。DecisionDx melanoma 的檢測量在 2026 年第二季相較 2026 年第一季亦增加約 3%,呈現溫和的季增長;但低於我們依歷史季節性通常會看到的季增幅度。我們認為此溫和的季增長,部分原因在於我們的商業團隊正在調整其客戶互動模式,以便在同一次客戶拜訪中支援三項產品。這是我們對業務成長所做的刻意投資。

  • DecisionDx-Melanoma remains the established foundation of our dermatological commercial portfolio. While the additional products, DecisionDx-SCC and AdvanceAD-Tx expand the value we can provide the same customer base and support growth over the medium and long term. Additionally, we continue to generate a substantial body of evidence to support the clinical performance and use of our DecisionDx melanoma test. In fact, during the second quarter, we were pleased to announce the publication of a prospective multicenter study demonstrating DecisionDx-Melanoma outperformed the Melanoma Institute of Australia nomogram, or MIA, in identifying patients at low and high risk of sentinel lymph node biopsy positivity.

    DecisionDx-Melanoma 仍是我們皮膚科商業產品組合中既有且穩固的基礎。而新增的產品 DecisionDx-SCC 與 AdvanceAD-Tx,則擴大了我們能為同一客戶群提供的價值,並在中長期支持成長。此外,我們持續累積大量證據,以支持 DecisionDx melanoma 檢測的臨床表現與使用。事實上,在第二季我們很高興宣布一項前瞻性多中心研究的發表,該研究顯示 DecisionDx-Melanoma 在辨識前哨淋巴結切片(sentinel lymph node biopsy)陽性之低風險與高風險患者方面,優於澳洲黑色素瘤研究所(Melanoma Institute of Australia)的列線圖(nomogram),即 MIA。

  • Importantly, patients predicted to be low risk by DecisionDx-Melanoma, that is, they were predicted to have a sentinel lymph node positivity rate of less than 5%, at an actual observed sentimental positivity rate of just 2.6%. Well below the National Comprehensive Cancer Network or NCCM 5% threshold used to consider avoiding a sentimental biopsy surgical procedure. These findings further demonstrate the value of integrating tumor biology with clinical pathologic factors to improve risk assessment, support more informed risk-aligned care and help identify patients who may safely forego the sentinel up to a biopsy surgical procedure.

    重要的是,DecisionDx-Melanoma 預測為低風險的患者,也就是預測其前哨淋巴結陽性率低於 5% 的患者,實際觀察到的前哨淋巴結陽性率僅為 2.6%。遠低於美國國家綜合癌症網絡(National Comprehensive Cancer Network,NCCN)所採用、用以考量是否避免進行前哨淋巴結切片手術程序的 5% 門檻。這些結果進一步證明,將腫瘤生物學與臨床病理因素整合以改善風險評估具有價值,可支持更充分且與風險相匹配的照護決策,並協助辨識可能可安全免除前哨淋巴結切片手術程序的患者。

  • Now let's turn to our tissue cipher test. During the quarter, we delivered 14,988 TissueCypher test reports, representing 63% growth compared to the second quarter of 2025. Based upon trends for the first half of the year, we believe our 2026 test report volume for tissue cipher will trend toward 50% to 52% growth compared to 2025.

    接著談我們的 TissueCypher 檢測。本季度我們交付 14,988 份 TissueCypher 檢測報告,較 2025 年第二季成長 63%。根據上半年趨勢,我們認為 2026 年 TissueCypher 的檢測報告量將趨近於較 2025 年成長 50% 至 52%。

  • Now, let's move on to our AdvanceAD-Tx test. During the second quarter, we delivered more than 1,000 orders. Given the test ability to guide systemic treatment selection for patients ages 12 and up with moderate to severe atopic dermatitis, we were particularly pleased that the AdvanceAD-Tx test was recently recognized with the Genomics Innovation Award in the 10th Annual MedTech Breakthrough Awards Program.

    接下來談我們的 AdvanceAD-Tx 檢測。第二季我們交付超過 1,000 筆訂單。鑑於該檢測能為 12 歲以上中度至重度異位性皮膚炎患者提供全身性治療選擇指引,我們特別高興 AdvanceAD-Tx 檢測近期在第 10 屆年度 MedTech Breakthrough Awards 計畫中獲頒 Genomics Innovation Award(基因體創新獎)。

  • In addition, we were encouraged by a new independent real-world clinical utility study for AdvanceAD-Tx presented in June at the revolutionizing atopic dermatitis meeting. In this multicenter study, only 54.3% or just over half of patients receiving baseline systemic therapy were initially on pathway concordant treatment. However, following testing with our AdvanceAD test, 97.8% of patients were initiated on molecularly concordant systemic therapy.

    此外,我們也受到一項新的、獨立的真實世界臨床效用研究所鼓舞;該研究於6月在「革新異位性皮膚炎」會議上發表,研究對象為AdvanceAD-Tx。在這項多中心研究中,接受基線全身性治療的患者中,僅有54.3%(也就是略高於一半)起初採用與途徑一致(pathway concordant)的治療。然而,在使用我們的AdvanceAD檢測進行檢測後,97.8%的患者開始接受與分子一致(molecularly concordant)的全身性治療。

  • The impact of AdvanceAD-Tx on assisting clinicians and patients with making molecularly aligned therapy decisions overlaps the market research we conducted in the summer and fall of 2025. That is, clinicians are searching for tools. in this case, our AdvanceAD-Tx test to assist them in making more informed, better therapy selections that align with an individual patient's underlying disease biology.

    AdvanceAD-Tx在協助臨床醫師與患者做出分子對齊的治療決策方面所帶來的影響,與我們在2025年夏季與秋季所進行的市場調查結果相互呼應。也就是說,臨床醫師正在尋找工具——在此情況下,就是我們的AdvanceAD-Tx檢測——以協助他們做出更有資訊依據、且更符合個別患者潛在疾病生物學的更佳治療選擇。

  • And with that, I would now turn the call over to Frank.

    接下來,我把電話會議交給Frank。

  • Frank Stokes - Chief Financial Officer

    Frank Stokes - Chief Financial Officer

  • Thank you, Derek. And good afternoon, everyone. Reiterating Derek's sentiment, we're proud to report excellent financial results for the second quarter of 2026.

    謝謝你,Derek。各位下午好。呼應Derek的感受,我們很自豪地報告2026年第二季的優異財務成果。

  • Revenue was $103.5 million for the quarter. Driven by continued strength in our core revenue drivers, primarily TissueCypher test volume growth and some improvement in ASP due in part to modifications in our accrual processes that were implemented earlier this year. For total revenue for 2026, we are raising our revenue guidance to $365 million to $375 million, up from the previously provided range of $345 million to $355 million.

    本季營收為1.035億美元。主要受我們核心營收驅動因素持續強勁所帶動,尤其是TissueCypher檢測量成長,以及平均銷售單價(ASP)有所改善;其中一部分原因是我們今年稍早實施的應計流程(accrual processes)調整。就2026年全年總營收而言,我們將營收指引上調至3.65億至3.75億美元,高於先前提供的3.45億至3.55億美元區間。

  • Our gross margin during the second quarter of 2026 was 74.9% compared to 77.3% in the second quarter of 2025. Our adjusted gross margin, which excludes the effects of intangible asset amortization related to our acquisitions and excludes the effects of revenue adjustments in the current period associated with test reports delivered in prior periods, was 76.3% for the quarter compared to 79.5% for the same period in 2025.

    2026年第二季的毛利率為74.9%,相較於2025年第二季的77.3%。本季調整後毛利率為76.3%,相較於2025年同期的79.5%;該調整後毛利率排除與我們收購相關的無形資產攤銷影響,並排除當期因前期交付之檢測報告而產生的營收調整影響。

  • For the full year 2026, we continue to expect our adjusted gross margin to be in the low to mid-70s range. Turning to expenses, our total operating expenses, including cost of sales for the second quarter of 2026, were $106.6 million compared to $90.4 million for the second quarter of 2025. Sales and marketing expenses for the quarter were $40.9 million compared to $35.1 million for the same period in 2025, primarily driven by higher personnel costs, higher expenses associated with travel and higher business administration costs.

    對於2026年全年,我們仍預期調整後毛利率將落在70%出頭至70%中段的區間。接著談費用,2026年第二季的總營業費用(包含銷貨成本)為1.066億美元,較2025年第二季的9,040萬美元增加。本季銷售與行銷費用為4,090萬美元,較2025年同期的3,510萬美元增加,主要由較高的人事成本、較高的差旅相關費用,以及較高的企業行政成本所驅動。

  • General and administrative expenses were $25.2 million for the quarter compared to $22.9 million for the same period in 2025, primarily attributable to higher personnel costs. Higher personnel costs reflect headcount expansions in our administrative functions as well as merit and annual inflationary wage adjustments for existing employees.

    本季一般及行政費用為2,520萬美元,較2025年同期的2,290萬美元增加,主要歸因於較高的人事成本。較高的人事成本反映了我們在行政職能的人力擴編,以及對現有員工進行的績效調薪與年度通膨性薪資調整。

  • Cost of sales expenses were $23.7 million in the second quarter of 2026 compared to $17.6 million in the second quarter of 2025. primarily due to higher expenses for lab supplies, higher personnel costs, and higher lab services costs. The increase in lab supplies and lab services costs reflects higher test report volumes. The increases in personnel costs reflect a higher headcount due to additions made to support business growth and response to growing test report volumes as well as merit and annual inflationary wage adjustments for existing employees.

    2026年第二季銷貨成本費用為2,370萬美元,較2025年第二季的1,760萬美元增加,主要由實驗室耗材費用增加、人事成本增加,以及實驗室服務成本增加所致。實驗室耗材與實驗室服務成本的上升反映了檢測報告量增加。人事成本的增加反映了為支持業務成長並因應不斷增加的檢測報告量而新增的人力,以及對現有員工進行的績效調薪與年度通膨性薪資調整。

  • R&D expenses were $14.5 million for the quarter compared to $12.8 million for the same period in 2025. Primarily due to higher personnel costs driven by increased headcount to support continued business growth as well as increased advisory board, clinical trial and travel costs related to our pipeline initiatives.

    本季研發(R&D)費用為1,450萬美元,較2025年同期的1,280萬美元增加。主要由較高的人事成本所致,該人事成本來自為支持持續的業務成長而增加的人力,以及與我們管線計畫相關的顧問委員會、臨床試驗與差旅成本增加。

  • Total non-cash stock-based compensation expense, which is allocated among cost of sales, R&D and SG&A expense was $11.6 million for the second quarter of 2026 compared to $11.2 million in the second quarter of 2025. Interest income was $2.4 million for the second quarter of 2026 compared to $2.9 million in the second quarter of 2025.

    本季非現金的股票基礎薪酬費用合計為1,160萬美元(分攤於銷貨成本、研發以及銷售、一般及行政費用之間),相較於2025年第二季的1,120萬美元。2026年第二季利息收入為240萬美元,較2025年第二季的290萬美元下降。

  • Our net loss for the second quarter of 2026 was $2.1 million compared to net income of $4.5 million for the second quarter of 2025. Diluted loss per share for the second quarter was $0.07 compared to diluted earnings per share of $0.15 for the same period in 2025. Adjusted EBITDA for the second quarter was $12.4 million compared to $10.4 million for the comparable period in 2025.

    2026年第二季淨損為210萬美元,相較於2025年第二季淨利450萬美元。本季稀釋後每股虧損為0.07美元,相較於2025年同期稀釋後每股盈餘0.15美元。本季調整後EBITDA為1,240萬美元,相較於2025年可比期間的1,040萬美元。

  • We continue to support and invest in growth initiatives while focusing on thoughtful expense control. We expect to achieve positive adjusted EBITDA for the third quarter, the fourth quarter and the full year 2026 and absent any strategic direction shift as well as for the full year 2027. Net cash provided by operating activities was $15.2 million for the second quarter of 2026 and net cash used in operating activities was $6.9 million for the six months ended June 30, 2026.

    我們在支持並投資成長計畫的同時,也專注於審慎的費用控管。我們預期在第三季、第四季以及2026年全年達成調整後EBITDA為正,並且在未出現任何策略方向轉變的情況下,2027年全年亦將如此。2026年第二季營運活動提供的淨現金為1,520萬美元;截至2026年6月30日止六個月,營運活動使用的淨現金為690萬美元。

  • Net cash used in investing activities was $41.8 million for the six months ended June 30, 2026, and consisted primarily of purchases of marketable investment securities of $109.6 million of property and equipment, partially offset by the maturities of marketable investment and debt securities along with the sale of equity securities.

    截至2026年6月30日止六個月,投資活動使用的淨現金為4,180萬美元,主要包括購入可供出售之投資證券,以及購置不動產及設備共計1.096億美元;部分由可供出售之投資與債務證券到期,以及出售股權證券所抵銷。

  • As of June 30, 2026, we had cash, cash equivalents and marketable investment securities of $266.8 million. Our strong balance sheet continues to provide financial flexibility to invest in our growth priorities. In closing, we delivered strong financial results through the first half of the year, continuing our longstanding history of consistent execution and performance excellence.

    截至2026年6月30日,我們持有的現金、約當現金及可供出售之投資證券為2.668億美元。我們強健的資產負債表持續提供財務彈性,使我們得以投資於成長優先事項。最後,我們在上半年交出強勁的財務成果,延續我們長期以來一貫的執行力與卓越績效表現。

  • I'll now turn the call back over to Derek.

    我現在把電話會議交回給Derek。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Thank you, Frank. In summary, we continue to execute at a high level, and I'm encouraged by the momentum we're carrying into the remainder of the year. None of this would be possible without the dedication of the entire Castle team. And I'm proud of what they have accomplished through their unwavered commitment to improving patient care.

    謝謝你,Frank。總結來說,我們持續以高水準執行,我也對我們帶著這股動能進入今年剩餘期間感到振奮。若沒有整個Castle團隊的投入,這一切都不可能實現。我也為他們透過堅定不移地致力於改善病患照護所達成的成果感到自豪。

  • Thank you for your continued interest in CASL. Now we'll be happy to take your questions.

    感謝各位持續關注CASL。現在我們很樂意回答各位的問題。

  • Operator

    Operator

  • (Operator Instructions) Max Masucci, Roth Capital Partners.

    (接線員指示) Max Masucci,Roth Capital Partners。

  • Max Masucci - Equity Analyst

    Max Masucci - Equity Analyst

  • Hi, good afternoon. Congrats on a great quarter. So, first question on AdvanceAD-Tx. Nice to see the unanimous panel vote for the crosswalk. Would love to get your initial thoughts on the rate associated with the crosswalk, whether the decision matched your expectations and just any updated expectations around the transition to a full commercial launch?

    嗨,下午好。恭喜本季表現出色。第一個問題關於AdvanceAD-Tx。很高興看到委員會對於crosswalk的一致性投票通過。想請教你們對於該crosswalk所對應的費率(rate)的初步看法、這項決定是否符合你們的預期,以及對於過渡到全面商業化上市(full commercial launch)的最新預期。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Yeah, good question, Max. Derek here. So first of all, in our analysis and before we submitted our request to be cross walked to that code. We believe that Castle, that was the most appropriate code. The crosswalk code is for a is for a test that predicts drug response to patients with psoriasis.

    是的,問得好,Max。我是Derek。首先,在我們進行分析並在提交申請、要求crosswalk到那個代碼之前,我們認為對Castle而言,那是最合適的代碼。這個crosswalk代碼是用於一項檢測,用來預測乾癬患者對藥物的反應。

  • The AdvanceAD-Tx test, as you know, predicts a systemic drug response to people with atopic dermatitis, similar kind of technology approaches, et cetera. So we thought that was the appropriate crosswalk to take care of that. Obviously, the panel did too. I think it was a 21 to zero vote in favor of cross walking. The rate of 3675, I think, is a very, very strong rate for our test. So, we are quite pleased with the panel's recommendation or earliest voting outcome there.

    如你所知,AdvanceAD-Tx 檢測可預測異位性皮膚炎患者對全身性藥物的反應,屬於類似的技術路徑等等。因此我們認為這是合適的對照(crosswalk)方式來處理這件事。顯然,委員會也是這麼認為。我想支持進行 crosswalk 的投票結果是 21 比 0。我認為 3675 的費率對我們的檢測來說是非常、非常強的費率。所以,我們對委員會的建議或當時的初步投票結果感到相當滿意。

  • And as you know, CMS will go ahead and take that input. And I think we see preliminary draft 2026 CLFS -- CLFS rate schedules in late September.

    而如你所知,CMS 接下來會採納該意見。我想我們會在 9 月下旬看到 2026 年 CLFS 的初步草案——CLFS 費率表。

  • So we're looking forward to seeing that affirm going forward. I think from an overall perspective, As that goes on with the clinical laboratory fee schedule effective January 1, 2026. That gives us a good benchmark in order to go ahead and set conversations with commercial payers as well regarding reimbursal rates, et cetera. So I think it's a very nice consistent plotting launch going forward here, which lets us get in a better position to open up a full launch in the future.

    所以我們很期待看到後續獲得確認並持續推進。從整體角度來看,隨著臨床實驗室費用表於 2026 年 1 月 1 日生效。這也給了我們一個很好的基準,讓我們能與商業保險支付方就給付費率等展開對話。因此我認為這是一個非常不錯且一致的推進節奏,讓我們能在未來更有利的位置上啟動全面上市。

  • Max Masucci - Equity Analyst

    Max Masucci - Equity Analyst

  • That's great. Second question, can you just give a bit more detail around the TissueCypher ASP trends in the second quarter, any one-timers? And just looking at the $20 million guidance rates, is that mostly captured by the improved TissueCipher volume growth outlook, or is there any expectation or improved expectation on the ASP side for TissueCypher? Frank?

    很好。第二個問題,你能否再多提供一些關於第二季 TissueCypher 平均售價(ASP)趨勢的細節,有沒有任何一次性因素?另外看你們 2,000 萬美元的指引水準,這主要是由 TissueCypher 量的成長展望改善所帶動,還是對 TissueCypher 的 ASP 端也有任何預期或更好的預期?Frank?

  • Frank Stokes - Chief Financial Officer

    Frank Stokes - Chief Financial Officer

  • We did have some pickup in ASP, Max. We've been selling the test for long enough now that we've got a bit more experience in terms of expected rates and actual collected rates. And so we were able to increase the ASP a bit in the first half of this year. Now having said that, I wouldn't expect to see the same stepwise increase in the back half.

    Max,我們的 ASP 的確有一些回升。我們銷售這項檢測已經夠久了,因此在預期費率與實際回收費率方面累積了更多經驗。所以我們在今年上半年能把 ASP 稍微提高一些。不過話說回來,我不預期下半年還會看到同樣階梯式的上升。

  • I think we will we are evaluating our payer experience and comparing that to our expectations. But I would not expect to see it again so most of the raise and our guide here is based on performance to date and you continued performance of our two primary revenue drivers uh decision next melanoma and TissueCypher.

    我想我們會、我們正在評估我們的支付方經驗,並把它與我們的預期做比較。但我不預期會再次出現;因此我們這次上調與指引主要是基於截至目前的表現,以及我們兩個主要營收驅動因素——DecisionDx-Melanoma 和 TissueCypher——的持續表現。

  • Operator

    Operator

  • Thomas Flaten, Lake Street Capital

    Thomas Flaten,Lake Street Capital

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Hey, good afternoon. Congrats on the quarter. A few questions. Given the volume growth on TissueCypher, anything you can share with us with respect to Salesforce expansion to really keep maximizing on this opportunity?

    嗨,下午好。恭喜這一季的表現。我有幾個問題。鑑於 TissueCypher 的量在成長,你們能否分享一下在擴編銷售團隊(Salesforce)方面的情況,以便持續最大化這個機會?

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • We have continued to sort of expand as we see territories hitting a forward-looking $2.5 million in revenue, Thomas. We don't necessarily give out specific numbers, but we're kind of floating around 100 sales representative of our sales territories for both our gastroenterology division and our dermatology division. We think that's probably pretty close to where it needs to be from a TissueCypher standpoint and dermatology sample for that matter.

    Thomas,我們持續在看到各區域達到前瞻性 250 萬美元營收水準時,進行某種程度的擴編。我們不一定會公布具體數字,但我們在胃腸科事業部與皮膚科事業部的銷售區域,銷售代表人數大概在 100 人左右浮動。我們認為就 TissueCypher 而言,以及皮膚科樣本業務也是如此,這大概已經接近所需的規模。

  • So I think we're kind of there. That being said, we had expansions last year and we had expansions late second quarter of this year here. We aren't even seeing the full fruits, I guess, of those expansion opportunities, but we feel pretty comfortable with a coming in from a volume year over year of 50%, 52% is what we believe we're on track for. So that's very quite positive.

    所以我想我們差不多到位了。話雖如此,我們去年有擴編,而今年第二季末也有擴編。我們甚至還沒有看到那些擴編機會的全部成果,但我們對於年對年量成長 50%、52% 的目標感到相當有把握,這也是我們認為目前正走在軌道上的數字。所以這是非常正面的。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • Got it. And then in the DETECT-AD study that you're doing with SciBase, how much of a window How much of a window do you need to have a clinical effect from a preventative perspective? Like how early does the test need to detect potential flares?

    了解。接著,在你們與 SciBase 共同進行的 DETECT-AD 研究中,從預防角度來看,你們需要多長的時間窗口才能產生臨床效果?例如,檢測需要多早偵測到可能的發作(flare)?

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • I think that's to be determined, I think, maybe based upon our market research, interactions with our investigators. And also, interactions with our medical dermatologists who are skin cancer doctors, but of course, the majority of what they see in their practice is basically atopic dermatitis in terms of diseases like this. The commentary there is that we have high-dose steroids. We can start those up in a couple of days in advance.

    我想這還有待確定,可能要基於我們的市場調研、與研究者的互動。也包括與我們的醫學皮膚科醫師(他們是皮膚癌醫師,但當然他們臨床上看到的大多數病例基本上是異位性皮膚炎這類疾病)的互動。那邊的回饋是,我們有高劑量類固醇。我們可以提前幾天開始使用。

  • You've got a topical JAK inhibitor that works pretty quick as well. So one could say you could go as short as a day and a half, two days in advance. We'd like to see if we can get earlier than that so it gives patients the time to maybe use less high-powered topical therapies to kind of keep control and keep their symptoms depressed or suppressed. So I think we'll kind of look at that, see if the data unwinds this fall preliminarily and get a good positive set for what it looks like.

    你也有外用型 JAK 抑制劑,起效也很快。所以有人會說,最短可以提前一天半、兩天。我們希望看看能不能更早,這樣患者就有時間也許使用較低強度的外用療法來維持控制,讓症狀保持在較低或被抑制的狀態。所以我想我們會持續觀察,看看今年秋天初步數據如何展開,並得到一個很好的正向結論,了解它看起來會是什麼樣子。

  • And that being said, the patient research that we have done recently in the second quarter of this year, there is such a acute need to be able to say, so you're telling me I could use a disposable, I mean not a disposable, a pen that'll be able to help me kind of understand my disease, control my disease as if I was a diabetic, wanting to really appreciate how do I stay dialed into being as normal as possible.

    另外,我們在今年第二季最近做的患者研究顯示,有非常迫切的需求:能夠說——所以你的意思是我可以用一個一次性……我是說不是一次性的,是一支筆狀裝置——來幫助我理解我的疾病、控制我的疾病,就像糖尿病患者一樣,真的想知道我如何能隨時掌握狀況,盡可能維持正常生活。

  • So that's a very, very positive feedback set there. So I think we have a range of what we could detect in advance of an actual player to be extremely clinically meaningful to both patients and their clinicians.

    所以那是一組非常、非常正面的回饋。因此我認為,在實際發作之前能提前偵測的時間範圍,只要落在其中,就可能對患者與臨床醫師都具有極高的臨床意義。

  • The other end of the equation that we are getting commentary on, which I think is quite positive as well. Is that once my player has resolved, if I can't get ahead of it, that is, how long do I stay on my sort of rescue medications before I could begin tapering those medications off? And again, we should be able to predict the front end. And if they can't suppress their flare completely and it actually becomes symptomatic, hopefully it's much more mild than if they didn't know that.

    我們在等式的另一端也收到一些回饋,我認為同樣相當正面。也就是:一旦我的發作已經緩解,如果我沒能提前介入——也就是說——在我可以開始逐步減量之前,我需要在所謂的救援用藥上維持多久?同樣地,我們應該能預測前端。而如果他們無法完全壓下發作、確實出現症狀,希望也會比在完全不知情的情況下輕微得多。

  • And the back end, rather than sort of having their sort of rescue medication treatment plan be sort of, well, once the symptoms resolve themselves, stay on your high dose steroids for what, five days, four days, three days. We believe that one of the uses of this device will be able to go ahead and help patients taper off of their rescue medications quicker or stay on longer if they still have this underlying heavy biological disease a pattern going on.

    至於後端,與其讓救援用藥的治療計畫變成某種——嗯,症狀一消失,就繼續用高劑量類固醇多久?五天、四天、三天——這種做法。我們相信這個裝置的一個用途,是能幫助患者更快地把救援用藥減量停用;或者如果仍存在底層較重的生物性疾病模式,就延長使用時間。

  • And then the final thing, which is quite exciting, is that we also have seen broad trends in the marketplace where patients would desire to sort of lengthen out their injection rates, lengthen out their use of oral therapies. So rather than kind of following what's on the label is to say, well, I've got copay exposure potentially. I don't like the idea of taking injections every two weeks.

    最後一點也相當令人興奮:我們也看到市場上有廣泛趨勢,患者希望把注射間隔拉長、把口服療法的使用間隔拉長。也就是說,不是照著標籤建議的方式——例如,我可能面臨自付額(copay)負擔。我不喜歡每兩週打一次針這件事。

  • Can I sort of take fewer injections and kind of lengthen out the frequency, but also still be controlled? And right now, when we talk to our dermatological colleagues, they're telling us that's all, of course, basically empirical.

    我能不能少打幾針、把頻率拉長,但仍然維持控制?而目前,當我們和皮膚科同業交流時,他們告訴我們,這些做法當然基本上都是憑經驗(empirical)在做。

  • The last patient I had here, Derek, was able to go from a sort of two-week injections of one drug to three and then to four. But when they got to five weeks, they all of a sudden had a heavy flare, limnology up. So, we said, we'll go back to four.

    我在這裡最後一位病人 Derek,原本是每兩週注射一次某種藥物,後來可以拉長到三週、再到四週。但當他們拉到五週時,突然出現嚴重復發,發炎指標上升。所以我們說,那就回到四週。

  • This device should be able to help a patient who wants to take that as a pathway of choice and let them potentially sort of lengthen out therapy dosage. Once they're well controlled to go ahead and just be on less medication over time, which I think most people would appreciate.

    這個裝置應該能幫助想把那條路徑作為首選的病人,讓他們有機會把治療劑量間隔拉長。一旦控制良好,就能隨時間推進逐步用更少的藥物,我想大多數人都會樂見其成。

  • Thomas Flaten - Analyst

    Thomas Flaten - Analyst

  • That's super helpful. Thank you.

    這非常有幫助。謝謝你。

  • Operator

    Operator

  • Mason Carrico, Stephens Inc.

    Mason Carrico,Stephens Inc.。

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Good afternoon. This is Ben on for Mason. Thanks for taking the questions.

    下午好。我是 Ben,代 Mason 發言。謝謝讓我們提問。

  • On the Q1 call, you guys noted that you started to see some quarterly seasonality beginning to emerge for TissueCypher. In your view, did you see any of that seasonality continue to play out in Q2? How should we think about the quarterly pacing for that test and the balance of the year? And then I guess as we look ahead to next year, should we think of that seasonality similar to 2026, or will that become, I guess, even more pronounced?

    在第一季電話會議上,你們提到開始看到 TissueCypher 出現一些季度季節性。以你們的觀點,第二季是否也延續了那種季節性?我們應該如何看待該檢測在季度間的節奏,以及今年剩餘時間的分布?另外,展望明年,我們應該把那種季節性視為與 2026 年類似,還是會變得更明顯?

  • Frank Stokes - Chief Financial Officer

    Frank Stokes - Chief Financial Officer

  • Frank, do you want to take that or want me to take that? Yeah, hey, Ben.

    Frank,你想回答,還是要我來?好的,嗨 Ben。

  • I think that we -- as tempting as it is to look sequentially in these tests, I think we really need to look on a trend line And if you look at the trend on TissueCypher, it's pretty steady growth. We had a little bit lower Q1, a little higher Q2. If you kind of smooth that over four quarters, you get closer to a pretty consistent trend.

    我認為——雖然很容易想用連續季度來看這些檢測,但我們其實需要看趨勢線。如果你看 TissueCypher 的趨勢,其實是相當穩定的成長。第一季稍低、第二季稍高;如果把四個季度平滑化,你會更接近一條相當一致的趨勢。

  • And so I would say in the first place, I would look sort of at that multi-quarter pathway. But secondly, yes, the seasonality we saw in Q1 did seem to be driven by fewer patient encounters. And just as we see on the derm side, we will probably continue to see that on TissueCypher. But we get to Q1, we'll look year-over-year and look at the multi-quarter trend rather than just sequentially.

    所以首先,我會建議從多季度的路徑來看。但其次,是的,我們在第一季看到的季節性似乎是由於病人就診次數較少所驅動。而且就像我們在皮膚科端看到的一樣,我們可能也會在 TissueCypher 上持續看到這種情況。等到第一季時,我們會用年對年來看,並觀察多季度趨勢,而不是只看序列變化。

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Got it. That makes sense. And then among the AdvanceAD-Tx orders that you've received to date, are you seeing signs of repeat ordering there? Increasing utilization among the initial cohort of accounts, or is that still mostly first-time trial orders? Thanks for taking the questions.

    了解。這樣說得通。另外,在你們迄今收到的 AdvanceAD-Tx 訂單中,你們是否看到重複下單的跡象?在最初那批帳戶中使用量是否提高,還是目前多半仍是首次試用訂單?謝謝讓我們提問。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • I don't have them -- raw data in front of me to answer that quantitatively, [Ben.]

    我手邊沒有——原始數據可以用來做定量回答,[Ben。]

  • But my recollection last time we reviewed that last month was that we are seeing both new ordering customers, as we sort of release this to additional customers, get their staff trained up or the clinician trained up on how to do this noninvasive scraping technique, get kits in the offices, et cetera. That we are seeing the sort of new ordering adoption we expect to see based upon the emphasis of putting it on from a Salesforce standpoint.

    但我記得上次我們在上個月回顧時,我們同時看到新客戶下單——因為我們逐步把這項產品釋出給更多客戶,讓他們的員工或臨床醫師受訓,學會如何進行這種非侵入性的刮取採樣技術,把試劑盒放到診所裡等等。我們確實看到符合預期的新下單採用情況,這也反映了我們從 Salesforce(銷售團隊)角度所投入的推動重點。

  • And we have, I think, very few clinicians who have sort of been one and done. So we do see heavy repeat users going on right now.

    而且我認為,幾乎沒有臨床醫師是那種只用一次就不再用的。所以我們現在確實看到大量的重複使用者。

  • Operator

    Operator

  • Subbu Nambi, Guggenheim Securities.

    Subbu Nambi,Guggenheim Securities。

  • Unidentified Participant

    Unidentified Participant

  • Hi. This is Ethan on or Subu. Thanks for taking our question. So what are your top priorities for R&D investments this year, and how much do you expect R&D to increase year-over-year?

    嗨。我是 Ethan,代 Subu 發言。謝謝回答我們的問題。那麼你們今年研發(R&D)投資的最高優先事項是什麼?以及你們預期研發費用年對年會增加多少?

  • Frank Stokes - Chief Financial Officer

    Frank Stokes - Chief Financial Officer

  • Thanks for the question. Yeah, I'm sorry. I tracked you.

    謝謝你的問題。是的,不好意思。我有聽到你。

  • Yeah, I think we'll continue to see some increase in R&D as we continue to focus on newly internally developed programs. I think you've heard us say before, we're very excited about the pipeline we have. And the way the story at Castle has evolved from the IPO days when we really had one kind of primary product to now two therapeutic areas and multiple products in each opportunity and pipeline. So we will see some increase, it's a deliberate investment.

    是的,我認為隨著我們持續聚焦於新近由內部開發的專案,我們會看到研發有一些增加。我想你們之前也聽我們說過,我們對現有的產品管線非常興奮。而 Castle 的故事也從 IPO 時期一路演進——當時我們基本上只有一個主要產品——到現在涵蓋兩個治療領域,且每個領域都有多個產品與多個機會與管線。所以研發會有一些增加,這是有意識的投資。

  • And it's -- we are running Castle for not only near-term, quarter-to-quarter growth, but also mid- and long-term growth to ensure long-term value creation well past 2030, 2035. So some increase, but I think in terms of priority, it will continue to be those programs within our existing therapeutic areas that line up so well on our commercial footprint.

    而且——我們經營 Castle 不僅是為了短期、逐季的成長,也為了中長期成長,確保在 2030、2035 年之後仍能創造長期價值。所以會有一些增加;但就優先順序而言,仍會以我們既有治療領域內、且與我們商業化佈局高度契合的那些專案為主。

  • Operator

    Operator

  • Matthew Parisi, KeyBanc Capital Markets.

    Matthew Parisi,KeyBanc Capital Markets。

  • Matthew Parisi - Analyst

    Matthew Parisi - Analyst

  • This is Matthew Parisi on for Paul Knight at KeyBanc Capital Markets. Congrats on the great quarter and thanks for the questions. You guys had a pickup in SEC volumes for the first time since it lost coverage and you stopped marketing the test. Could you provide some color on what is driving the resurgence?

    我是 Matthew Parisi,代 KeyBanc Capital Markets 的 Paul Knight 發言。恭喜你們交出很棒的一季,也謝謝回答問題。你們的 SCC 檢測量在失去給付覆蓋、且你們停止行銷該檢測後,首次出現回升。能否提供一些背景,說明這波回升是由什麼驅動的?

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • I think the number one driver of SCC volumes is the clinical value existing customers see in the tests and how they use it to manage their patients' high-risk LMS cell carcinomas. We did what I think we talked about at first quarter earnings. Allow sounds like a funny word, encourage, I guess, our sales force to say, hey, our predominant focus is and will remain on the short-term cutaneous melanoma. But you have this atopic dermatitis test, you have the squamous cell carcinoma test that's at great clinical value.

    我認為 SCC 檢測量的第一大驅動因素,是既有客戶在臨床上看到這項檢測的價值,以及他們如何用它來管理病人的高風險鱗狀細胞癌。我們做了——我想我們在第一季財報時也談過——「允許」聽起來有點怪,我想應該說是「鼓勵」我們的銷售團隊去說:嘿,我們主要的重點是、也將持續是短期內的皮膚黑色素瘤。

  • We need to make sure that we are spending some time on those elements, a small amount of time, but sometimes -- so I think it's a combination of existing users, more working days in the second quarter certainly and some return to some promotional time with our sales force.

    我們需要確保也在這些項目上花一些時間——時間不需要很多,但有時候——所以我認為這是既有使用者、第二季工作天數較多,當然還有我們銷售團隊回到一定程度的推廣時間,這幾個因素的組合。

  • Matthew Parisi - Analyst

    Matthew Parisi - Analyst

  • Thank you. And then if you could provide an update on the Previse GI pipeline test?

    謝謝。另外,你能否更新一下 Previse GI 的管線檢測進度?

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Sure. So we have, as you know, when we acquired Previse, we had a portfolio of IP that came out of Hopkins was licensed in their provides. They had a tissue-based assay, Esopredict that we made available in the first, I guess, early first quarter of this year. As a reflexive test or backstop test in those few cases that we couldn't get a TissueCypher result to a physician. Under the expectation that, hey, the most well-documented, the most valuable test that predicts progression of Barrett's disease to high-grade dysplasia or cancer is the tissue cipher test.

    當然。如你所知,我們收購 Previse 時,取得了一組 IP 組合,來源是 Hopkins(約翰霍普金斯)並授權給他們。他們有一個以組織為基礎的檢測 Esopredict,我們在今年第一季初(我想是第一季早期)已經提供使用。它作為反射性檢測或後備檢測,用於少數我們無法把 TissueCypher 結果提供給醫師的情況。我們的前提是:在預測巴瑞特食道進展到高度異型增生或癌症方面,證據最充分、價值最高的檢測是 TissueCypher。

  • But if we're unable for features of the way the biopsy was taken, et cetera, not to get a spatial omics test to work, it would offer up Esopredict as a backup in those few cases. Regarding the cell collection device, Previse had also worked out a sponge. Which was fit into a capsule attached to a string that went through the capsule and the expectation was it won't swallow that, let it go down into your lower esophagus, maybe upper stomach or lower esophagus.

    但如果因為活檢取樣方式等因素,導致空間組學檢測無法運作,我們就會在那少數案例中提供 Esopredict 作為備援。至於細胞採集裝置,Previse 也開發了一種海綿裝置。它被放入一個膠囊中並連著一條線,線穿過膠囊;原本的設想是讓你吞下去,讓它下到下段食道,可能到上胃部或下段食道。

  • The capsule dissolves, the sponge pops out and you pull the sponge back out with that string. We have protocols for cell collection devices that are in design and sort of ready to go here. So I would say probably to update that probably maybe first half of next year is probably the right timing.

    膠囊會溶解,海綿會彈出,然後你用那條線把海綿再拉出來。我們針對正在設計、也算是快要就緒的細胞採集裝置已有相關流程。所以我會說,若要更新這部分,可能明年上半年大概是比較合適的時間點。

  • Matthew Parisi - Analyst

    Matthew Parisi - Analyst

  • Thank you. Appreciate the questions.

    謝謝。感謝提問。

  • Operator

    Operator

  • Kyle Mikson, Canaccord Genuity.

    Kyle Mikson,Canaccord Genuity。

  • Alex Cason - Analyst

    Alex Cason - Analyst

  • Hi, this is Alex B. Cason along for Kyle Nixon. Thank you for taking our questions and congrats again on the strong quarter. Just following up on something I was previously asked, we're about halfway through the year now. On TissueCypher, you exited 2023 at about 26% patient penetration, with about 2% to 3% incremental penetration each of the next two years, about 31 exiting '25.

    大家好,我是代替 Kyle Nixon 的 Alex B. Cason。謝謝你們回答我們的問題,也再次恭喜本季表現強勁。延續我先前被問到的一點,我們現在大約已經過完上半年。就 TissueCypher 而言,你們在 2023 年底的病患滲透率約為 26%,接下來兩年每年約增加 2% 到 3%,到 2025 年底約為 31%。

  • And you followed that up with, you know, a really strong first half and particularly 2Q. Just understand that there's a lot of runway here, but could you qualify the opportunity ahead for this test? Does any low-hanging fruit remain or could you perhaps have to see some step-up in expenses to reach the rest of this opportunity over time. Just trying to get a sense of how durable this level of growth is going forward. Thanks.

    而你們接著也提到,上半年表現非常強,尤其是第二季。我理解這裡還有很長的成長跑道,但能否請你們說明一下這項檢測未來的機會空間?是否還有任何「低垂的果實」可摘,或是你們可能需要隨時間增加費用投入,才能觸及剩餘的機會?我只是想了解,往後這樣的成長水準有多持久。謝謝。

  • Frank Stokes - Chief Financial Officer

    Frank Stokes - Chief Financial Officer

  • Yeah, just clarifying there. We think we exited 25% at about 10%, maybe 11% or 12% patient penetration on the addressable patient market.

    好的,先澄清一下。我們認為截至 2025 年(應為先前所述期間)時,在可觸及的病患市場中,病患滲透率大約是 10%,可能 11% 或 12%。

  • And if the numbers we provided earlier today would get us to maybe 15% middle teens, we are certainly going to begin to face the headlines of big numbers. And by definition, the easier positions to convert are the first ones and the ones that come later are perhaps take a bit more work. So at some point, we'll begin to see that.

    如果按照我們今天稍早提供的數字,可能會到 15% 左右、也就是 10% 中段到後段。那我們當然就會開始面對「基數變大」的現實。而按定義來說,最容易轉換的通常是最先的一批,後面那些可能需要多花一些力氣。所以在某個時間點,我們會開始看到這種情況。

  • But I think importantly, at this juncture in the life of that test and the marketing of that test, we still have maybe way too many, you might think, physicians who haven't yet had the chance to be educated on the clinical benefit of using tissue side for their barrier's esophagus patients. And so lots of runway ahead as we convert those physicians that don't yet have the opportunity. We will begin to get into those big numbers and begin to get into that more mature phase, but that test has a long way to go yet.

    但我認為重要的是,在這項檢測的生命週期與行銷推廣的現階段,我們仍然有很多——你可能會覺得甚至太多——醫師,還沒有機會被教育了解對其巴瑞特食道(Barrett’s esophagus)病患使用 TissueCypher 的臨床效益。因此,當我們把那些尚未有機會接觸的醫師逐步轉換過來,前方仍有很長的跑道。我們會逐步進入更大的數字、也會進入更成熟的階段,但這項檢測距離那一步還很遠。

  • Alex Cason - Analyst

    Alex Cason - Analyst

  • Got it. Thank you. And just on the Novitas LCD, which impacts the Kispert lab and the MolDX LCD, which impacts the Phoenix lab. Does mid-27 kind of remain a reasonable time frame for potential return of payment for SEC? And importantly, have there been any recent chats or review of new data that perhaps invokes incremental confidence in the ability to flip one of these decisions specifically? Thank you.

    了解。謝謝。另外關於 Novitas 的 LCD(影響 Kispert 實驗室)以及 MolDX 的 LCD(影響 Phoenix 實驗室)。對於 SEC 可能恢復給付而言,2027 年中左右仍算是合理的時間框架嗎?更重要的是,最近是否有任何新的溝通或新數據的審閱,讓你們對於能夠翻轉其中一項決定(特別是其中之一)更有信心?謝謝。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • So we have no, I guess, public commentary about data discussions with either Medicare contractor. As you may know, there is no timeline for their response. We've heard nothing, by the way, negative, so don't take that commentary as negative. From a standpoint of a return to coverage. We did model out based upon a very limited database that maybe would take a year, a year and a quarter to have those Medicare contractors work through the reconsideration request. That would be sort of in the second half of this year.

    所以我們沒有任何——我想說——關於與任一 Medicare 承包商進行數據討論的公開評論。如你所知,他們回覆沒有既定時程。順帶一提,我們也沒有聽到任何負面訊息,所以不要把這段話解讀成負面。就恢復給付/涵蓋而言,我們基於非常有限的資料庫做了模型推估,可能需要一年到一年又一季,讓這些 Medicare 承包商完成對重新審議(reconsideration)申請的處理。那大概會落在今年下半年。

  • So I think, you know, we're expecting to see daylight in the second half of 2026, I think is a reasonable expectation. Once a draft was posted, we don't really have any sense right now is would they work quicker to go from draft to final or would they follow the currently path, which is roughly taken the entire year to finalize the draft LCD to final. So I think guidance has been pretty consistent, which is to say if we see a positive draft coverage LCD coming out from either one of the Medicare contractors, in the latter half of this year or the second-half of this year. I should say, then we should anticipate roughly a year later of regaining coverage for Medicare beneficiaries. Which would be a fantastic opportunity to really advance their care.

    因此我認為,合理的預期是我們在 2026 年下半年看到曙光。一旦草案公布後,我們目前也不太清楚他們從草案到定案會加快,還是會沿用目前的流程——也就是大約花一整年把草案 LCD 定稿為最終版本。所以我認為我們的指引一直相當一致:也就是說,如果我們在今年下半年看到任一 Medicare 承包商發布正向的草案涵蓋 LCD,那麼我們應該預期大約一年後,才能為 Medicare 受益人恢復涵蓋。那將是推動其照護大幅前進的絕佳機會。

  • So I think that's how I would kind of view that per se. We, of course, always are generating additional publications, additional evidence development to support the correct decision to enable Medicare beneficiaries to benefit from this test on a broad basis. But that's being worked through right now.

    所以我大致會這樣看待。當然,我們也一直在產出更多發表、更多證據開發,以支持做出正確的決策,讓 Medicare 受益人能在更廣泛的基礎上受惠於這項檢測。但目前這些都還在推進中。

  • Alex Cason - Analyst

    Alex Cason - Analyst

  • Got it. Thank you very much.

    了解。非常感謝。

  • Operator

    Operator

  • Mark Massaro, BTIG.

    Mark Massaro,BTIG。

  • Unidentified Participant

    Unidentified Participant

  • Hey, guys. This is Megan on for Mark. Thank you for taking our questions. I'm curious about the FDA breakthrough device designation. Can you just give maybe a ballpark range or any additional color for when you're thinking about the timing of the FDA approval?

    嗨,各位。我是代替 Mark 的 Megan。謝謝你們回答我們的問題。我想請教 FDA 的突破性醫療器材認定(breakthrough device designation)。你們能否就你們預期的 FDA 核准時間點,提供一個大概的區間或更多說明?

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Oh, approval. So I would separate those two things here, Megan. So the breakthrough device designation enables us to sort of go to the front line, get other special features, I guess you would say, in terms of the view of that of a submission. I don't know if we've talked publicly about our timing of that.

    喔,核准。Megan,我會把這兩件事分開來看。突破性醫療器材認定讓我們在某種程度上可以走到前線,在提交申請的審視上獲得一些額外的特殊機制(可以這麼說)。我不確定我們是否曾公開談過我們的時間規劃。

  • I would think we might expect to have FDA clearance/approval maybe later on this year, early next year. BGD gives you an opportunity to really have a more powder in your gun, I guess you would say, in addressing the FDA. There are certain expectations on both sides of the table.

    我認為我們可能會在今年稍晚、或明年初取得 FDA 的核准/許可。BGD 讓你在與 FDA 溝通時,某種程度上有更多「彈藥」(可以這麼說)。在桌子的兩端都有一些特定的期待。

  • Unidentified Participant

    Unidentified Participant

  • Awesome, thank you guys. And you continue to deliver strong unit growth in melanoma volumes this quarter. We're just curious if you've seen any changes in the competitive environment in melanoma over the recent months?

    太好了,謝謝各位。另外,你們本季在黑色素瘤檢測量方面持續交出強勁的單位成長。我們想了解,過去幾個月你們是否看到黑色素瘤領域的競爭環境有任何變化?

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Yeah, we had talked through, I guess first quarter earnings was a high year-over-year growth rate, but we hopefully tried to speak intuitively, which is to say, we think at the end of the year, we're going to come in with between kind of mid to high single-digit growth. I think we're right on track to achieve what our internal goals are. So we're seeing the promotional responsiveness, the value of our test in the marketplace hasn't really changed a whole lot, and that's fantastic, of course.

    是的,我們在第一季財報時有談到,年對年的成長率很高,但我們也希望用更直觀的方式說明:我們認為到年底,我們的成長會落在中到高個位數的區間。我覺得我們正按計畫達成內部目標。所以我們看到推廣的回應度、以及我們檢測在市場上的價值,並沒有太大改變,這當然非常好。

  • Unidentified Participant

    Unidentified Participant

  • Great. Thank you, guys.

    很好。謝謝各位。

  • Operator

    Operator

  • [Puneet Zoda, Leerink.]

    [Puneet Zoda,Leerink。]

  • Unidentified Participant

    Unidentified Participant

  • Hi, this is Philip on for Puneet. Thanks for the question and congrats on a great quarter. I know there were a lot of questions on TissueCypher already, but it's all right. I just want to double-click more on volume growth this quarter. A big step up, obviously, both year-over-year and sequentially after the seasonal dip in the first quarter.

    嗨,我是代替 Puneet 的 Philip。謝謝提問,也恭喜本季表現出色。我知道關於 TissueCypher 已經有很多問題了,但沒關係。我想再更深入追問一下本季的量能成長。在第一季季節性下滑之後,無論年對年或季對季,這一季都明顯大幅跳升。

  • Just wanted to ask, can you talk a bit more about what drove the reacceleration? Was it mostly seasonal combined with execution? Or is there anything else you could call out in terms of growth mix or deficit use that may have played a role?

    我只是想問一下,您能否再多談一些是什麼因素推動了重新加速?主要是季節性因素加上執行力的結合嗎?或者就成長組合或赤字使用(deficit use)方面,還有沒有其他您可以點出的因素可能也發揮了作用?

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Frank, you or me?

    Frank,你來回答還是我來?

  • Frank Stokes - Chief Financial Officer

    Frank Stokes - Chief Financial Officer

  • Yeah, sure. So we don't yet have the procedures data for the second quarter. And as we noted in the last call, first quarter was lower in terms of upper endoscopy procedures than we've seen in prior quarters. But again, I think that the important focus here is on that multi-quarter trend, maybe trailing four, you draw a nice trend line and you see the tissue ciphers fairly steady, fairly in line with where it's been through those maybe trailing three or four quarters.

    好的,當然。所以我們目前還沒有第二季的手術量(procedures)數據。而且如同我們在上次電話會議中提到的,第一季的上消化道內視鏡(upper endoscopy)手術量比我們在先前幾季看到的要低。但我認為這裡重要的重點仍然是看多季的趨勢,可能看最近四季,畫出一條趨勢線,你會看到組織(tissue)的指標相當穩定,與過去最近三到四季的水準大致一致。

  • We believe we probably -- I don't know yet. I don't know if we did. We probably saw more procedures in the quarter than we saw in Q1. But when you trend that out, it's just good solid increased penetration on the volume side, the tissue side through the last year.

    我們認為我們可能——我現在還不知道。我不確定我們是否真的如此。我們可能在本季看到的手術量比Q1更多。但把趨勢拉長來看,過去一年在量的面向、組織端的面向,都只是穩健扎實地提升滲透率。

  • Unidentified Participant

    Unidentified Participant

  • Got it. That makes sense. And then I also wanted to ask, did you see any impact from ACA disenrollment on your test volumes this quarter? just with enhanced marketplace subsidies now lapsed and coverage down in 2026. Are you seeing it in either ordering volumes or shift towards self-pay that pressures collections? And is a younger, more commercially insured franchise like AdvanceAD more exposed than melanoma and tissue safe? I know it's more Medicare skewed.

    了解。這很合理。另外我也想問,本季ACA退保(disenrollment)對你們的檢測量有任何影響嗎?因為加強版的市集補貼(enhanced marketplace subsidies)現在已到期,且2026年的保險覆蓋率下降。你們是否在開單量(ordering volumes)上看到影響,或是是否出現更多轉向自費(self-pay)而對回款(collections)造成壓力?以及像AdvanceAD這種客群較年輕、商業保險占比較高的產品線,是否比melanoma和tissue safe更容易受到影響?我知道後者更偏向Medicare。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Think we have any visibility to be able to comment on that question, I guess I would say.

    我想我們是否有任何能見度可以評論這個問題——我大概只能這麼說。

  • Unidentified Participant

    Unidentified Participant

  • Okay, no worries.

    好的,沒問題。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • I don't think -- I was trying to get about our test report data for second quarter. I don't recall our reimbursement team saying there was a change in the mix of insured patients commercially, Medicare patients commercially, Medicare managed patients commercially or Medicaid. Medicaid, we've always had a very low exposure, a couple of points, those all.

    我不認為——我剛剛在想我們第二季的檢測報告數據。我不記得我們的報銷團隊有提到商業保險、Medicare、商業Medicare管理式(Medicare managed)或Medicaid的病患組合有任何變化。至於Medicaid,我們一直以來曝險都非常低,大概只有幾個百分點,就這些。

  • So I guess you would say, well, if there are less people ordering tests or going to doctors because they chose to back out of their insurance, we have no way to see that, I guess you would say?

    所以我想你可以說,如果因為有人選擇退出保險而導致看醫生或開檢測的人變少,我們也沒有辦法看得到這件事,應該可以這麼說?

  • Unidentified Participant

    Unidentified Participant

  • Got it. Fair enough. Thank you so much.

    了解。可以理解。非常感謝。

  • Operator

    Operator

  • Robbie Bamberger, Baird.

    Robbie Bamberger,Baird。

  • Unidentified Participant

    Unidentified Participant

  • Hi, guys. This is Josh on for Robbie. Thank you for taking my questions.

    嗨,各位。我是Josh,代替Robbie提問。謝謝你們回答我的問題。

  • You know, first, I guess just again on kind of the lower-than-expected seasonal volumes there for decision DX melanoma in 2Q. You know, given some of those sales force items you mentioned. It's kind of what informs confidence in that mid to high single digit growth for the year. And, you know, I guess how should we think about year-over-year volume growth in 3Q and 4Q for that test as well, too? Thanks.

    首先,我想再回到2Q DecisionDx melanoma 低於預期的季節性量能。考量你們提到的一些銷售團隊相關事項,是什麼讓你們對全年中到高個位數成長仍有信心?另外,對於這項檢測,3Q與4Q的年對年量成長應該如何看待?謝謝。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • So I guess confidence as we have an enterprise model, I guess, similar to you that you do on the outside and we're on the inside and based upon what we see in our model against actuals, we believe we're still tracking toward what we thought we would do, which is kind of mid to high single digits for the year. In terms of third and fourth quarter, second-half expectations, I guess that would sort of take our first half and get a range to see how you get to the second half from a full year-end volume growth. is why I would approach that.

    我想我們的信心來自於我們有一個企業模型(enterprise model),我想跟你們外部使用的模型類似,而我們是在內部使用;根據我們在模型中看到的情況與實際數據對照,我們相信目前仍在朝我們原先預期的方向前進,也就是全年中到高個位數的成長。至於第三、第四季,也就是下半年展望,我會用上半年的表現作為基礎,推導出一個區間,看看要如何從全年量成長目標回推下半年需要達到的水準;我會用這種方式來思考。

  • Unidentified Participant

    Unidentified Participant

  • Great. And then I was just wondering, too, how you're kind of thinking about the progression of AdvanceAD-Tx rollout here. Any plans to kind of further broaden this out for the rest of the year? And maybe by the end of the year, how many clinician offices are you maybe trying to target here as part of your phased approach? Thanks.

    很好。另外我也想請教,你們目前如何看待AdvanceAD-Tx的推廣進程?今年剩餘時間是否有計畫進一步擴大推廣?以及可能到年底,依照你們分階段的策略,大概希望觸及多少家臨床醫師診所作為目標?謝謝。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • So we are still managing sort of, I guess, field-based expectations. So maybe the best way to go ahead and say it is that our field force in dermatology, I believe, for the remainder of the year, at least certainly third quarter, is relatively 80%, 85% or 85% focused on cutaneous melanoma from sort of a call-focused commission bonus perspective, with the remaining 15% being I guess more heavier weighted to atopic different to the AdvanceAD tests and some on SEC from a bonus standpoint, just to make sure that we're balancing out both near-term needs, mid-term needs, and long-term needs.

    所以我們仍在管理、我想可以說是第一線(field-based)的預期。也許最好的說法是:我們皮膚科的外勤團隊,我認為在今年剩餘時間、至少在第三季,從以拜訪重點(call-focused)的佣金獎金角度來看,大約有80%、85%或85%聚焦在皮膚型黑色素瘤(cutaneous melanoma)。

  • So that will certainly, I think, change a bit of the acceleration in a positive manner for AdvanceAD without having us hopefully see a sacrifice in melanoma focus. We are still trying to manage volume. So we don't get too far ahead of ourselves. But as you would know, if you don't create demand, then there isn't much a reason to have Medicare or commercial payers to really step up and pay attention.

    因此我認為這確實會在不希望犧牲黑色素瘤聚焦的前提下,讓AdvanceAD的加速在正向方向上有所改變。我們仍在嘗試管理量能,避免我們跑得太快、超前太多。但如你所知,如果你不創造需求,那麼也就沒有太多理由讓Medicare或商業保險支付方真正站出來並加以關注。

  • And as we sort of create volume, we can also model collections against our internal collection model. As we get more confident with that towards the end of this year, our last half of the third quarter, that will let us go ahead and say, now we should plan on opening this up a bit more in 2027.

    而當我們逐步創造量能時,我們也可以把回款(collections)與我們內部的回款模型進行建模比對。當我們在今年底、第三季後半段對此更有信心時,就能進一步說:那麼我們應該規劃在2027年把推廣範圍再擴大一些。

  • Operator

    Operator

  • We have reached the end of the question-and-answer session. I would now like to turn the floor back over to Derek Maetzold for closing comments.

    問答環節到此結束。現在我想把時間交回給Derek Maetzold做結語。

  • Derek Maetzold - President, Chief Executive Officer, Founder, Director

    Derek Maetzold - President, Chief Executive Officer, Founder, Director

  • Thank you, operator. This concludes our second quarter 2026 earnings call. We thank you again for joining us today and for your continued interest in Castle Biosciences.

    謝謝,接線員。本次2026年第二季財報電話會議到此結束。再次感謝各位今天的參與,以及持續關注Castle Biosciences。

  • Operator

    Operator

  • This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.

    今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。